The Approval Process in Action

Life Sciences Tools & DiagnosticsMedical DevicesRegenerative MedicineBiotechnology / Pharmaceuticals

Source: The Life Sciences Report and Visual Capitalist (5/1/13)

What catalysts in the drug development process move biotech company stocks? The savvy investor must know what steps in the U.S. Food and Drug Administration's approval process can propel a stock up or down. From drug discovery to the much-anticipated PDUFA date, The Life Sciences Report and the Visual Capitalist have collaborated on an infographic that describes both the process and related catalysts.

DarioHealth: Chronic Care Platform Drives Value
Source: Streetwise Reports (06/23/2026)

DarioHealth targets the booming digital health market with a multi-condition platform backed by 27 ADA studies. See pipeline growth, analyst targets, and key catalysts for investors.

Grey Matters Health Inc. Advances US Alzheimer's Clinics
Source: Streetwise Reports (06/23/2026)

Grey Matters Health Inc. closes CA$1.25M financing to launch brain-specific PET clinics targeting the expanding Alzheimer's diagnostics market and early detection demand.

Explore Traws Pharma's strategy in respiratory antivirals, cash runway to 2027, pipeline backups, and analyst perspectives amid evolving biopharma funding and flu market needs for retail investors.

Rezolute's Ersodetug Advances in Rare Hypoglycemia Treatment Amid Pharma Growth
Source: Streetwise Reports (06/20/2026)

Explore Rezolute Inc.'s progress with Ersodetug for hyperinsulinism, including ENDO 2026 data, analyst ratings, and sector trends for retail investors seeking biotech opportunities.

Sernova Biotherapeutics leverages its Cell Pouch technology and recent FDA orphan drug designation to address type 1 and type 3c diabetes amid a growing global market, supported by improved financial stability for retail investors.